29 June 2021
Pioneering Swedish diagnostics company Elypta aims to prevent cancer mortality by enabling earlier cancer detection. In this video, members of the Elypta leadership team — Chief Executive Officer, Karl Bergman, and Vice President of R&D, Karin Mattsson — discuss innovation in glycosaminoglycan (GAG) extraction and measurement as novel biomarkers for cancer and describe how working closely with Merck* as a contract manufacturing partner has enabled Elypta to produce the first standardized extraction kit for full-spectrum human GAG quantification in body fluids.
*The Life Science business of Merck operates as MilliporeSigma in the U.S. and Canada.